-
PROVIDERS
Read more
Browse our latest selection of abstracts, manuscripts, and presentations.
-
LIFE SCIENCES
LIVE WEBINAR
Optimizing research with RWD: How Lens accelerates time to insights in drug discovery.
Register now. -
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
Resources
Webinars
-
04/12/2024Liquid biopsy’s role in biomarker-driven NSCLC Management
Discover how Dr. Wade Iams of Vanderbilt University is utilizing liquid biopsy as a valuable tool for broad biomarker detection and monitoring resistance mechanisms to therapeutic pressure in NSCLC.Speakers: Wade Iams, MD
Watch replay
Assistant Professor of Medicine, Vanderbilt-Ingram Cancer Center
Gary I. Grad, MD
Senior Medical Oncologist, Tempus
Ezra Cohen, MD FRCPSC, FASCO
Chief Medical Officer of Oncology, Tempus -
04/03/2024Leveraging RNA sequencing to identify actionable biomarkers in NSCLC management
Join us in a dynamic discussion with Dr. Marc Matrana of Ochsner Health as he shares how RNA sequencing revealed new treatment options for his patient when DNA seq was unsuccessful identifying key, actionable biomarkers.Speakers: Marc Matrana, MD, FACP, MS
Watch replay
System Director of Precision Medicine, Ochsner Health
Gary I. Grad, MD
Senior Medical Oncologist, Tempus
Ezra Cohen, MD FRCPSC, FASCO
Chief Medical Officer of Oncology, Tempus -
02/28/2024Unlocking the power of RNA in drug development
Hear insights from industry leaders on understanding, leveraging, and validating RNA in the drug development process.Speakers: Calvin Chao, MD
Watch replay
SVP of Medical Affairs, Tempus
Brian Rini, MD, FASCO
Chief of Clinical Trials, Hematology & Oncology, Vanderbilt University Medical Center
Scott Haake, MD, PhD
Assistant Professor of Medicine, Hematology & Oncology, Vanderbilt University Medical Center
Nilofer Azad, MD
Professor of Oncology Co-Director, Developmental Therapeutics Program/Phase I Program Co-Leader, Cancer Genetics and Epigenetics, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University -
10/17/2023
Impact of multimodal data in translational science
In this panel session we spoke to Translational Scientists who have been utilizing multi-modal insights in their daily work and discussed what new information can come to light by utilizing these tools.Speakers: Iker Huerga
Watch replay
EVP, Life Science Strategy & RWD, Tempus
Jonathan Dry
VP, Scientific Discovery, Tempus
Charles Lin, PhD
SVP, TRN Mapping, KronosBio
Pedram Razavi, MD, PhD
Director, Breast Translational Program and Molecular Tumor Board, Memorial Sloan Kettering Cancer Center -
09/20/2023
Evidence & guidelines-based application of PGx in mental health
Learn how evidence and guidelines-based pharmacogenomics (PGx) can be a useful tool to inform medication selection and dosing in psychiatry.Speakers: Dr. Jon Durrani
Watch replay
Practicing Neurologist, Dayton Center for Neurological Disorders
Dr. Muneer Ali
Child, Adolescent and Adult Psychiatrist & Senior Director of Medical Affairs, Neuro/Psychiatry, Tempus -
08/22/2023
The evolving landscape in precision oncology: key research findings from the 2023 ASCO Annual Meeting
Hear from Tempus moderators Dr. Ezra Cohen and Dr. Calvin Chao as they engage in a multi-disciplinary discussion around practice changing approaches to somatic and germline testing with Dr. Ramaswamy Govindan from Siteman Cancer Center and Dr. Cathy Handy Marshall from Johns Hopkins Medicine.Speakers: Ezra Cohen, MD
Watch replay
Chief Medical Officer of Oncology, Tempus
Calvin Chao, MD
Senior Vice President of Medical Affairs, Tempus
Dr. Ramaswamy Govindan
Professor of Medicine, Washington University in St. Louis, Siteman Cancer Center
Catherine Handy Marshall, MD, MPH
Assistant Professor of Oncology, Johns Hopkins Medicine -
08/18/2023
An analysis on the utility of liquid biopsy (LBx) throughout clinical development
Listen to industry leaders discuss longitudinal endpoints for disease progression, the evolving role of liquid biopsy within drug development, and the value of methylation in combination with liquid biopsy.Speakers: Nike Beaubier, MD
Watch replay
Senior Vice President, Life Science Pathology, Tempus
Ezra Cohen, MD
Chief Medical Officer of Oncology, Tempus
Michael Yasiejko
General Manager and Executive Vice President, Tempus -
05/23/2023Accelerate clinical trial enrollment and site activation
Learn how TriHealth uses the TIME network to identify trial subjects and rapidly activate new clinical trials within its oncology portfolio within an average of ~10 business days.Speakers: Amy Gordon Franzen
Watch replay
SVP, Trials Business, Tempus
James F Maher, MD
Oncologist, TriHealth
Jason Claes, MBA, MSM, GRCRA
Clinical Research Manager, TriHealth -
05/18/2023Tempus’ FDA approval and insights on the use of companion diagnostics in clinical development
Tempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel.Speakers: Elaine Katrivanos
Watch replay
VP, Regulatory Affairs, Tempus
Lauren Silvis
SVP, External Affairs, Tempus
Kate Sasser
Chief Scientific Officer, Tempus -
03/30/2023
NGS in advanced breast cancer: exploring recent clinical advancements
Learn more about breast cancer management with NGS. We explore the potential utility of complementary solid tumor and liquid biopsy testing in informing treatment decisions, as well as patient management strategies in the post CDK4/6 inhibitor therapy setting.Speakers: Calvin Chao, MD
Watch replay
SVP of Medical Affairs, Tempus
Cynthia Ma, MD, PhD
Professor of Medicine, Washington University in St. Louis, Siteman Cancer Center
Massimo Cristofanilli, MD, FACP
Chief, Breast Medical Oncology, Sandra Edward Meyer Cancer Center at Weill Cornell Medicine